Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding 'Submission Of Letter Of Offer For Buy-Back Upto 16,00,000 Equity Shares'.
JAGSNPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.5 pts more than Nifty Microcap 250 and 1.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Jagsonpal Pharmaceuticals Limited has announced a buyback of up to 16,00,000 fully paid-up equity shares (representing 2.38% of total paid-up share capital) at a price of ₹250 per share in cash. The total buyback size is ₹40 crores and represents 18.35% of the company's aggregate paid-up capital and free reserves as per audited financials for FY2025, which is within the statutory 25% limit. The record date for determining eligible shareholders was May 04, 2026, and the buyback window runs from May 08, 2026 to May 14, 2026. The buyback will be executed through the tender offer route via BSE. Both small shareholders (holding shares worth up to ₹2 lakh) and general category shareholders have an entitlement ratio of 47 shares for every 637 shares held. The company states the buyback will be funded from internal accruals and not borrowed funds.
The buyback offers shareholders a chance to exit at ₹250 per share, which represents a substantial premium over the face value of ₹2 per share. For shareholders, participating in the buyback provides liquidity and a return of capital. The reduction in share count could improve per-share metrics like EPS for remaining shareholders.